MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will be participating on a panel discussion entitled, “Innovative Treatment Approaches to Orphan CNS Developmental Disorders” at the JMP Securities Life Sciences Conference on Wednesday, June 19th, 2019 at 10:00 a.m. EDT. The panel will focus on novel pharmacological approaches to treating orphan genetic disorders that primarily impact the central nervous system.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central and peripheral nervous system.
The company is headquartered in Bresso near Milan, Italy. Xadago®
(safinamide) has received marketing authorization for the treatment of
Parkinson’s disease in the European Union, Switzerland, the US,
Australia, Canada, Brazil, and Colombia and is commercialized by
Newron’s partner Zambon. US WorldMeds holds the commercialization rights
in the USA. Meiji Seika has the rights to develop and commercialize the
compound in Japan and other key Asian territories. In addition to
Xadago® for Parkinson’s disease, Newron has a strong pipeline of
promising treatments for rare disease patients at various stages of
clinical development, including sarizotan for patients with Rett
syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing Evenamide as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia. For more information, please visit: www.newron.com
